160 related articles for article (PubMed ID: 25062073)
1. Use of an early disease-modifying drug adherence measure to predict future adherence in patients with multiple sclerosis.
Kozma CM; Phillips AL; Meletiche DM
J Manag Care Spec Pharm; 2014 Aug; 20(8):800-7. PubMed ID: 25062073
[TBL] [Abstract][Full Text] [Related]
2. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
Prescott JD; Factor S; Pill M; Levi GW
J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
[TBL] [Abstract][Full Text] [Related]
3. One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program.
Groeneweg M; Forrester SH; Arnold B; Palazzo L; Zhu W; Yoon P; Scearce T
J Manag Care Spec Pharm; 2018 May; 24(5):458-463. PubMed ID: 29694287
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
Hirsch JD; Gonzales M; Rosenquist A; Miller TA; Gilmer TP; Best BM
J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
[TBL] [Abstract][Full Text] [Related]
5. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.
Ivanova JI; Bergman RE; Birnbaum HG; Phillips AL; Stewart M; Meletiche DM
J Med Econ; 2012; 15(3):601-9. PubMed ID: 22376190
[TBL] [Abstract][Full Text] [Related]
6. Comparing adherence and persistence across 6 chronic medication classes.
Yeaw J; Benner JS; Walt JG; Sian S; Smith DB
J Manag Care Pharm; 2009; 15(9):728-40. PubMed ID: 19954264
[TBL] [Abstract][Full Text] [Related]
7. Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy.
Wade RL; Kindermann SL; Hou Q; Thase ME
J Manag Care Pharm; 2014 Jan; 20(1):76-85. PubMed ID: 24372461
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
[TBL] [Abstract][Full Text] [Related]
9. Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.
Lage MJ; Carroll CA; Fairman KA
J Med Econ; 2013 Sep; 16(9):1146-53. PubMed ID: 23844620
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries.
Hirsch JD; Rosenquist A; Best BM; Miller TA; Gilmer TP
J Manag Care Pharm; 2009; 15(1):32-41. PubMed ID: 19125548
[TBL] [Abstract][Full Text] [Related]
11. Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data.
Carroll CA; Fairman KA; Lage MJ
BMC Health Serv Res; 2014 Jul; 14():286. PubMed ID: 24986083
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.
Burkhard A; Toliver J; Rascati K
J Manag Care Spec Pharm; 2021 Jul; 27(7):915-923. PubMed ID: 34185555
[No Abstract] [Full Text] [Related]
14. Predictors of Nonadherence to Topical Intraocular Pressure Reduction Medications Among Medicare Members: A Claims-Based Retrospective Cohort Study.
Sheer R; Bunniran S; Uribe C; Fiscella RG; Patel VD; Chandwani HS
J Manag Care Spec Pharm; 2016 Jul; 22(7):808-817a. PubMed ID: 27348282
[TBL] [Abstract][Full Text] [Related]
15. A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan.
Abughosh SM; Wang X; Serna O; Henges C; Masilamani S; Essien EJ; Chung N; Fleming M
J Manag Care Spec Pharm; 2016 Jan; 22(1):63-73. PubMed ID: 27015053
[TBL] [Abstract][Full Text] [Related]
16. Using Previous Medication Adherence to Predict Future Adherence.
Kumamaru H; Lee MP; Choudhry NK; Dong YH; Krumme AA; Khan N; Brill G; Kohsaka S; Miyata H; Schneeweiss S; Gagne JJ
J Manag Care Spec Pharm; 2018 Nov; 24(11):1146-1155. PubMed ID: 30362915
[TBL] [Abstract][Full Text] [Related]
17. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis.
Zuckerman AD; DeClercq J; Simonson D; Zagel AL; Turco E; Banks A; Wawrzyniak J; Rightmier E; Blevins A; Choi L
Mult Scler Relat Disord; 2023 Jul; 75():104738. PubMed ID: 37182475
[TBL] [Abstract][Full Text] [Related]
18. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
19. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
[No Abstract] [Full Text] [Related]
20. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
